Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Gastroenterology
Published in: BMC Gastroenterology 1/2013

Open Access 01-12-2013 | Research article

Ozagrel hydrochloride, a selective thromboxane A2 synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice

Authors: Yoshiro Tomishima, Yoichi Ishitsuka, Naoya Matsunaga, Minako Nagatome, Hirokazu Furusho, Mitsuru Irikura, Shigehiro Ohdo, Tetsumi Irie

Published in: BMC Gastroenterology | Issue 1/2013

Login to get access

Abstract

Background

Overdosed acetaminophen (paracetamol, N-acetyl-p-aminophenol; APAP) causes severe liver injury. We examined the effects of ozagrel, a selective thromboxane A2 (TXA2) synthase inhibitor, on liver injury induced by APAP overdose in mice.

Methods

Hepatotoxicity was induced to ICR male mice by an intraperitoneal injection with APAP (330 mg/kg). The effects of ozagrel (200 mg/kg) treatment 30 min after the APAP injection were evaluated with mortality, serum alanine aminotransferase (ALT) levels and hepatic changes, including histopathology, DNA fragmentation, mRNA expression and total glutathione contents. The impact of ozagrel (0.001-1 mg/mL) on cytochrome P450 2E1 (CYP2E1) activity in mouse hepatic microsome was examined. RLC-16 cells, a rat hepatocytes cell line, were exposed to 0.25 mM N-acetyl-p-benzoquinone imine (NAPQI), a hepatotoxic metabolite of APAP. In this model, the cytoprotective effects of ozagrel (1–100 muM) were evaluated by the WST-1 cell viability assay.

Results

Ozagel treatment significantly attenuated higher mortality, elevated serum alanine aminotransferase levels, excessive hepatic centrilobular necrosis, hemorrhaging and DNA fragmentation, as well as increase in plasma 2,3-dinor thromboxane B2 levels induced by APAP injection. Ozagrel also inhibited the hepatic expression of cell death-related mRNAs induced by APAP, such as jun oncogene, FBJ osteosarcoma oncogene (fos) and C/EBP homologous protein (chop), but did not suppress B-cell lymphoma 2-like protein11 (bim) expression and hepatic total glutathione depletion. These results show ozagrel can inhibit not all hepatic changes but can reduce the hepatic necrosis. Ozagrel had little impact on CYP2E1 activity involving the NAPQI production. In addition, ozagrel significantly attenuated cell injury induced by NAPQI in RLC-16.

Conclusions

We demonstrate that the TXA2 synthase inhibitor, ozagrel, dramatically alleviates liver injury induced by APAP in mice, and suggest that it is a promising therapeutic candidate for the treatment of APAP-induced liver injury.
Appendix
Available only for authorised users
Literature
1.
Graham GG, Scott KF, Day RO: Tolerability of paracetamol. Drug Saf. 2005, 28 (3): 227-240. 10.2165/00002018-200528030-00004.CrossRefPubMed
2.
Li C, Martin BC: Trends in emergency department visits attributable to acetaminophen overdoses in the United States: 1993–2007. Pharmacoepidemiol Drug Saf. 2011, 20 (8): 810-818. 10.1002/pds.2103.CrossRefPubMed
3.
Craig DG, Bates CM, Davidson JS, Martin KG, Hayes PC, Simpson KJ: Overdose pattern and outcome in paracetamol-induced acute severe hepatotoxicity. Br J Clin Pharmacol. 2011, 71 (2): 273-282. 10.1111/j.1365-2125.2010.03819.x.CrossRefPubMedPubMedCentral
4.
Gow PJ, Jones RM, Dobson JL, Angus PW: Etiology and outcome of fulminant hepatic failure managed at an Australian liver transplant unit. J Gastroenterol Hepatol. 2004, 19 (2): 154-159. 10.1111/j.1440-1746.2004.03273.x.CrossRefPubMed
5.
Wei G, Bergquist A, Broomé U, Lindgren S, Wallerstedt S, Almer S, Sangfelt P, Danielsson A, Sandberg-Gertzén H, Lööf L, et al: Acute liver failure in Sweden: etiology and outcome. J Intern Med. 2007, 262 (3): 393-401. 10.1111/j.1365-2796.2007.01818.x.CrossRefPubMed
6.
7.
Bechmann LP, Jochum C, Kocabayoglu P, Sowa JP, Kassalik M, Gieseler RK, Saner F, Paul A, Trautwein C, Gerken G, et al: Cytokeratin 18-based modification of the MELD score improves prediction of spontaneous survival after acute liver injury. J Hepatol. 2010, 53 (4): 639-647. 10.1016/j.jhep.2010.04.029.CrossRefPubMed
8.
Antoine DJ, Jenkins RE, Dear JW, Williams DP, McGill MR, Sharpe MR, Craig DG, Simpson KJ, Jaeschke H, Park BK: Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity. J Hepatol. 2012, 56 (5): 1070-1079. 10.1016/j.jhep.2011.12.019.CrossRefPubMedPubMedCentral
9.
Raucy JL, Lasker JM, Lieber CS, Black M: Acetaminophen activation by human liver cytochromes P450IIE1 and P450IA2. Arch Biochem Biophys. 1989, 271 (2): 270-283.CrossRefPubMed
10.
Patten CJ, Thomas PE, Guy RL, Lee M, Gonzalez FJ, Guengerich FP, Yang CS: Cytochrome P450 enzymes involved in acetaminophen activation by rat and human liver microsomes and their kinetics. Chem Res Toxicol. 1993, 6 (4): 511-518. 10.1021/tx00034a019.CrossRefPubMed
11.
Lee SS, Buters JT, Pineau T, Fernandez-Salguero P, Gonzalez FJ: Role of CYP2E1 in the hepatotoxicity of acetaminophen. J Biol Chem. 1996, 271 (20): 12063-12067. 10.1074/jbc.271.20.12063.CrossRefPubMed
12.
Gonzalez FJ: Role of cytochromes P450 in chemical toxicity and oxidative stress: studies with CYP2E1. Mutat Res. 2005, 569 (1–2): 101-110.CrossRefPubMed
13.
Hanawa N, Shinohara M, Saberi B, Gaarde WA, Han D, Kaplowitz N: Role of JNK translocation to mitochondria leading to inhibition of mitochondria bioenergetics in acetaminophen-induced liver injury. J Biol Chem. 2008, 283 (20): 13565-13577. 10.1074/jbc.M708916200.CrossRefPubMedPubMedCentral
14.
Hinson JA, Pike SL, Pumford NR, Mayeux PR: Nitrotyrosine-protein adducts in hepatic centrilobular areas following toxic doses of acetaminophen in mice. Chem Res Toxicol. 1998, 11 (6): 604-607. 10.1021/tx9800349.CrossRefPubMed
15.
LoGuidice A, Boelsterli UA: Acetaminophen overdose-induced liver injury in mice is mediated by peroxynitrite independently of the cyclophilin D-regulated permeability transition. Hepatology. 2011, 54 (3): 969-978. 10.1002/hep.24464.CrossRefPubMed
16.
James LP, McCullough SS, Lamps LW, Hinson JA: Effect of N-acetylcysteine on acetaminophen toxicity in mice: relationship to reactive nitrogen and cytokine formation. Toxicol Sci. 2003, 75 (2): 458-467. 10.1093/toxsci/kfg181.CrossRefPubMed
17.
Masubuchi Y, Suda C, Horie T: Involvement of mitochondrial permeability transition in acetaminophen-induced liver injury in mice. J Hepatol. 2005, 42 (1): 110-116. 10.1016/j.jhep.2004.09.015.CrossRefPubMed
18.
Masubuchi Y, Sugiyama S, Horie T: Th1/Th2 cytokine balance as a determinant of acetaminophen-induced liver injury. Chem Biol Interact. 2009, 179 (2–3): 273-279.CrossRefPubMed
19.
Jaeschke H, Williams CD, Ramachandran A, Bajt ML: Acetaminophen hepatotoxicity and repair: the role of sterile inflammation and innate immunity. Liver Int. 2012, 32 (1): 8-20. 10.1111/j.1478-3231.2011.02501.x.CrossRefPubMed
20.
Culo F, Renić M, Sabolović D, Rados M, Bilić A, Jagić V: Ketoconazole inhibits acetaminophen-induced hepatotoxicity in mice. Eur J Gastroenterol Hepatol. 1995, 7 (8): 757-762.PubMed
21.
North TE, Babu IR, Vedder LM, Lord AM, Wishnok JS, Tannenbaum SR, Zon LI, Goessling W: PGE2-regulated wnt signaling and N-acetylcysteine are synergistically hepatoprotective in zebrafish acetaminophen injury. Proc Natl Acad Sci USA. 2010, 107 (40): 17315-17320. 10.1073/pnas.1008209107.CrossRefPubMedPubMedCentral
22.
Rolin S, Masereel B, Dogné JM: Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol. 2006, 533 (1–3): 89-100.CrossRefPubMed
23.
Ishitsuka Y, Moriuchi H, Isohama Y, Tokunaga H, Hatamoto K, Kurita S, Irikura M, Iyama K, Irie T: A selective thromboxane A2 (TXA2) synthase inhibitor, ozagrel, attenuates lung injury and decreases monocyte chemoattractant protein-1 and interleukin-8 mRNA expression in oleic acid-induced lung injury in guinea pigs. J Pharmacol Sci. 2009, 111 (2): 211-215. 10.1254/jphs.09128SC.CrossRefPubMed
24.
Xavier FE, Blanco-Rivero J, Sastre E, Badimón L, Balfagón G: Simultaneous inhibition of TXA(2) and PGI(2) synthesis increases NO release in mesenteric resistance arteries from cirrhotic rats. Clin Sci (Lond). 2010, 119 (7): 283-292. 10.1042/CS20090536.CrossRef
25.
Watson S, Daly M, Dawood B, Gissen P, Makris M, Mundell S, Wilde J, Mumford A: Phenotypic approaches to gene mapping in platelet function disorders - identification of new variant of P2Y12, TxA2 and GPVI receptors. Hämostaseologie. 2010, 30 (1): 29-38.PubMed
26.
Cavar I, Kelava T, Vukojević K, Saraga-Babić M, Culo F: The role of prostaglandin E2 in acute acetaminophen hepatotoxicity in mice. Histol Histopathol. 2010, 25 (7): 819-830.PubMed
27.
Cavar I, Kelava T, Heinzel R, Culo F: The role of prostacyclin in modifying acute hepatotoxicity of acetaminophen in mice. Coll Antropol. 2009, 33 (Suppl 2): 25-29.PubMed
28.
Reilly TP, Brady JN, Marchick MR, Bourdi M, George JW, Radonovich MF, Pise-Masison CA, Pohl LR: A protective role for cyclooxygenase-2 in drug-induced liver injury in mice. Chem Res Toxicol. 2001, 14 (12): 1620-1628. 10.1021/tx0155505.CrossRefPubMed
29.
Guarner F, Boughton-Smith NK, Blackwell GJ, Moncada S: Reduction by prostacyclin of acetaminophen-induced liver toxicity in the mouse. Hepatology. 1988, 8 (2): 248-253. 10.1002/hep.1840080210.CrossRefPubMed
30.
Baciewicz AM, Baciewicz FA: Ketoconazole and fluconazole drug interactions. Arch Intern Med. 1993, 153 (17): 1970-1976. 10.1001/archinte.1993.00410170042004.CrossRefPubMed
31.
Nakazawa M, Iizuka K, Ujiie A, Hiraku S, Ohki S: [Research and development of ozagrel, a highly selective inhibitor of TXA2 synthase]. Yakugaku Zasshi. 1994, 114 (12): 911-933.PubMed
32.
Dogné JM, de Leval X, Benoit P, Delarge J, Masereel B: Thromboxane A2 inhibition: therapeutic potential in bronchial asthma. Am J Respir Med. 2002, 1 (1): 11-17. 10.1007/BF03257158.CrossRefPubMed
33.
Ishitsuka Y, Moriuchi H, Hatamoto K, Yang C, Takase J, Golbidi S, Irikura M, Irie T: Involvement of thromboxane A2 (TXA2) in the early stages of oleic acid-induced lung injury and the preventive effect of ozagrel, a TXA2 synthase inhibitor, in guinea-pigs. J Pharm Pharmacol. 2004, 56 (4): 513-520. 10.1211/0022357023150.CrossRefPubMed
34.
Matsunaga N, Nakamura N, Yoneda N, Qin T, Terazono H, To H, Higuchi S, Ohdo S: Influence of feeding schedule on 24-h rhythm of hepatotoxicity induced by acetaminophen in mice. J Pharmacol Exp Ther. 2004, 311 (2): 594-600. 10.1124/jpet.104.069062.CrossRefPubMed
35.
Latchoumycandane C, Goh CW, Ong MM, Boelsterli UA: Mitochondrial protection by the JNK inhibitor leflunomide rescues mice from acetaminophen-induced liver injury. Hepatology. 2007, 45 (2): 412-421. 10.1002/hep.21475.CrossRefPubMed
36.
Reisman SA, Buckley DB, Tanaka Y, Klaassen CD: CDDO-Im protects from acetaminophen hepatotoxicity through induction of Nrf2-dependent genes. Toxicol Appl Pharmacol. 2009, 236 (1): 109-114. 10.1016/j.taap.2008.12.024.CrossRefPubMedPubMedCentral
37.
Omura T, Sato R: The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem. 1964, 239: 2370-2378.PubMed
38.
Kondo Y, Ishitsuka Y, Kadowaki D, Nagatome M, Saisho Y, Kuroda M, Hirata S, Irikura M, Hamasaki N, Irie T: Phosphoenolpyruvic acid, an intermediate of glycolysis, attenuates cellular injury induced by hydrogen peroxide and 2-deoxy-D-glucose in the porcine proximal kidney tubular cell line, LLC-PK 1. J Heal Sci. 2010, 56 (6): 727-732. 10.1248/jhs.56.727.CrossRef
39.
Kondo Y, Ishitsuka Y, Kadowaki D, Kuroda M, Tanaka Y, Nagatome M, Irikura M, Hirata S, Sato K, Maruyama T, et al: Phosphoenolpyruvic acid, an intermediary metabolite of glycolysis, as a potential cytoprotectant and anti-oxidant in HeLa cells. Biol Pharm Bull. 2012, 35 (4): 606-611. 10.1248/bpb.35.606.CrossRefPubMed
40.
Yoshimi Y, Fujimura M, Myou S, Tachibana H, Hirose T: Effect of thromboxane A2 (TXA2) synthase inhibitor and TXA2 receptor antagonist alone and in combination on antigen-induced bronchoconstriction in guinea pigs. Prostaglandins Other Lipid Mediat. 2001, 65 (1): 1-9. 10.1016/S0090-6980(01)00099-5.CrossRefPubMed
41.
Sasaki K, Miyake H, Kinoshita T, Ikeyama S, Tashiro S: Protective effect of FK506 and thromboxane synthase inhibitor on ischemia-reperfusion injury in non-heart-beating donor in rat orthotopic liver transplantation. J Med Invest. 2004, 51 (1–2): 76-83.CrossRefPubMed
42.
Xu H, Lee CY, Clemens MG, Zhang JX: Inhibition of TXA synthesis with OKY-046 improves liver preservation by prolonged hypothermic machine perfusion in rats. J Gastroenterol Hepatol. 2008, 23 (7 Pt 2): e212-e220.CrossRefPubMed
43.
Beyer RP, Fry RC, Lasarev MR, McConnachie LA, Meira LB, Palmer VS, Powell CL, Ross PK, Bammler TK, Bradford BU, et al: Multicenter study of acetaminophen hepatotoxicity reveals the importance of biological endpoints in genomic analyses. Toxicol Sci. 2007, 99 (1): 326-337. 10.1093/toxsci/kfm150.CrossRefPubMed
44.
Nakagawa H, Maeda S, Hikiba Y, Ohmae T, Shibata W, Yanai A, Sakamoto K, Ogura K, Noguchi T, Karin M, et al: Deletion of apoptosis signal-regulating kinase 1 attenuates acetaminophen-induced liver injury by inhibiting c-Jun N-terminal kinase activation. Gastroenterology. 2008, 135 (4): 1311-1321. 10.1053/j.gastro.2008.07.006.CrossRefPubMed
45.
Nagy G, Kardon T, Wunderlich L, Szarka A, Kiss A, Schaff Z, Bánhegyi G, Mandl J: Acetaminophen induces ER dependent signaling in mouse liver. Arch Biochem Biophys. 2007, 459 (2): 273-279. 10.1016/j.abb.2006.11.021.CrossRefPubMed
46.
Badmann A, Keough A, Kaufmann T, Bouillet P, Brunner T, Corazza N: Role of TRAIL and the pro-apoptotic Bcl-2 homolog Bim in acetaminophen-induced liver damage. Cell Death Dis. 2011, 2: e171-10.1038/cddis.2011.55.CrossRefPubMedPubMedCentral
47.
Wiggins CM, Tsvetkov P, Johnson M, Joyce CL, Lamb CA, Bryant NJ, Komander D, Shaul Y, Cook SJ: BIM(EL), an intrinsically disordered protein, is degraded by 20S proteasomes in the absence of poly-ubiquitylation. J Cell Sci. 2011, 124 (Pt 6): 969-977.CrossRefPubMed
48.
Hinds MG, Smits C, Fredericks-Short R, Risk JM, Bailey M, Huang DC, Day CL: Bim, Bad and Bmf: intrinsically unstructured BH3-only proteins that undergo a localized conformational change upon binding to prosurvival Bcl-2 targets. Cell Death Differ. 2007, 14 (1): 128-136. 10.1038/sj.cdd.4401934.CrossRefPubMed
49.
50.
Saito C, Zwingmann C, Jaeschke H: Novel mechanisms of protection against acetaminophen hepatotoxicity in mice by glutathione and N-acetylcysteine. Hepatology. 2010, 51 (1): 246-254. 10.1002/hep.23267.CrossRefPubMedPubMedCentral
51.
Gunawan BK, Liu ZX, Han D, Hanawa N, Gaarde WA, Kaplowitz N: c-Jun N-terminal kinase plays a major role in murine acetaminophen hepatotoxicity. Gastroenterology. 2006, 131 (1): 165-178. 10.1053/j.gastro.2006.03.045.CrossRefPubMed
Metadata
Title
Ozagrel hydrochloride, a selective thromboxane A2 synthase inhibitor, alleviates liver injury induced by acetaminophen overdose in mice
Authors
Yoshiro Tomishima
Yoichi Ishitsuka
Naoya Matsunaga
Minako Nagatome
Hirokazu Furusho
Mitsuru Irikura
Shigehiro Ohdo
Tetsumi Irie
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Gastroenterology / Issue 1/2013
Electronic ISSN: 1471-230X
DOI
https://doi.org/10.1186/1471-230X-13-21

Other articles of this Issue 1/2013

BMC Gastroenterology 1/2013 Go to the issue

Case report

Emergency cholecystectomy and hepatic arterial repair in a patient presenting with haemobilia and massive gastrointestinal haemorrhage due to a spontaneous cystic artery gallbladder fistula masquerading as a pseudoaneurysm

Research article

Improvement of long-term outcomes in pancreatic cancer and its associated factors within the gemcitabine era: a collaborative retrospective multicenter clinical review of 1,082 patients

Correspondence

An analysis of online messages about probiotics

Research article

Linear echoendoscope-guided ERCP for the diagnosis of occult common bile duct stones

Case report

Penile metastasis from primary cholangiocarcinoma: the first case report

Research article

Metabonomic analysis of liver tissue from BALB/c mice with d-galactosamine/lipopolysaccharide-induced acute hepatic failure
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits